Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential role of fecal volatile organic compounds as biomarkers of chemically induced intestinal inflammation in mice.
Reade S, Williams JM, Aggio R, Duckworth CA, Mahalhal A, Hough R, Pritchard DM, Probert CS. Reade S, et al. Among authors: hough r. FASEB J. 2019 Mar;33(3):3129-3136. doi: 10.1096/fj.201800076RR. Epub 2018 Oct 25. FASEB J. 2019. PMID: 30359099
We provide evidence that the identification of disease-associated VOC concentration ranges, combined with specific marker compounds, would potentially increase the likelihood of finding an inflammatory bowel disease-specific fecal VOC marker profile.-Reade, S., Williams, J. M., A …
We provide evidence that the identification of disease-associated VOC concentration ranges, combined with specific marker compounds, would p …
Macrophage-Specific NF-κB Activation Dynamics Can Segregate Inflammatory Bowel Disease Patients.
Papoutsopoulou S, Burkitt MD, Bergey F, England H, Hough R, Schmidt L, Spiller DG, White MHR, Paszek P, Jackson DA, Martins Dos Santos VAP, Sellge G, Pritchard DM, Campbell BJ, Müller W, Probert CS. Papoutsopoulou S, et al. Among authors: hough r. Front Immunol. 2019 Sep 11;10:2168. doi: 10.3389/fimmu.2019.02168. eCollection 2019. Front Immunol. 2019. PMID: 31572379 Free PMC article. Clinical Trial.
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M, Burridge S, Kirkwood AA, Bonney D, Watts K, Shenton G, Jalowiec KA, O'Reilly MA, Roddie C, Castleton A, Clesham K, Nicholson E, Alajangi R, Prabhu S, George L, Uttenthal B, Gabelli M, Neill L, Besley C, Chaganti S, Wynn RF, Bartram J, Chiesa R, Lucchini G, Pavasovic V, Rao A, Rao K, Silva J, Samarasinghe S, Vora A, Clark P, Cummins M, Marks DI, Amrolia P, Hough R, Ghorashian S. Oporto Espuelas M, et al. Among authors: hough r. Blood Cancer J. 2024 Apr 15;14(1):66. doi: 10.1038/s41408-024-01038-2. Blood Cancer J. 2024. PMID: 38622139 Free PMC article.
Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts.
Lum SH, James B, Ottaviano G, Ewins AM, Patrick K, Ali S, Carpenter B, Silva J, Tewari S, Furness C, Thomas A, Shenton G, Bonney D, Moppett J, Hambleton S, Gennery AR, Amrolia P, Gibson B, Hough R, Rao K, Slatter M, Wynn R. Lum SH, et al. Among authors: hough r. Transplant Cell Ther. 2024 Mar;30(3):314.e1-314.e12. doi: 10.1016/j.jtct.2023.12.005. Epub 2023 Dec 14. Transplant Cell Ther. 2024. PMID: 38103787 Free article.
324 results